Sofosbuvir add-on to ribavirin for chronic hepatitis E in a cirrhotic liver transplant recipient: a case report

• Main Authors: Montserrat Fraga, Jérôme Gouttenoire, Roland Sahli, Haithem Chtioui, Cristina Marcu, Manuel Pascual, Darius Moradpour, Julien Vionnet
• Format: Article
• Language: English
• Published: BMC 2019-05-01
• Series: BMC Gastroenterology
• Subjects: Chronic hepatitis; Decompensated cirrhosis; Hepatitis E virus; Rabbit HEV; Solid organ transplantation
• Online Access: http://link.springer.com/article/10.1186/s12876-019-0995-z

Abstract Background Chronic hepatitis E represents an emerging challenge in organ transplantation, as there are currently no established treatment options for patients who fail to clear hepatitis E virus (HEV) following reduction of immunosuppressive therapy and/or treatment with ribavirin. Sofosbuvir has shown antiviral activity against HEV in vitro but clinical utility in vivo is unknown. Case presentation We describe a 57-year-old liver transplant recipient with decompensated graft cirrhosis due to chronic hepatitis E. Reduction of immunosuppressive treatment as well ribavirin alone for 4 months did not result in viral clearance. Add-on of sofosbuvir for 6 months was associated with HEV RNA becoming undetectable in plasma. However, sustained viral clearance could not be achieved. Conclusions Sofosbuvir may have some antiviral activity against HEV when added to ribavirin. However, this did not suffice to yield sustained viral clearance. Our well-characterized observation emphasizes the need for new treatment options to cure chronic hepatitis E in the setting of organ transplantation.